ReviewFrontiers in neurology2025
Low NIHSS score in large vessel occlusion stroke: optimal treatment and clinical controversies.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.Pharmaceutics · 2026Review
- Endovascular treatment and clinical outcomes in minor ischemic stroke due to large-vessel disease: a retrospective study.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute ischemic stroke caused by large vessel occlusion (LVO) with low National Institutes of Health Stroke Scale (NIHSS) scores (≤5) presents a critical clinical dilemma regarding optimal management. While endovascular thrombectomy (EVT) is established for moderate-to-severe strokes, its role in milder cases remains controversial, balancing potential benefits against risks of intracranial hemorrhage and procedural complications. This review synthesizes evidence from observational studies, registry data, and meta-analyses comparing EVT with best medical therapy (including intravenous thrombolysis and antiplatelet treatment) in this population. Key findings indicate no significant difference in 90-day functional outcomes between EVT and medical management; across observational cohorts, EVT has been associated with higher symptomatic intracranial hemorrhage (sICH) and a possible increase in 90-day mortality, but these estimates derive from non-randomized data and may reflect selection bias and residual confounding. Subgroup analyses highlight the influence of occlusion location (proximal vs. distal), risk of early neurological deterioration (END), time window, and bridging therapy on treatment decisions: proximal occlusions (e.g., internal carotid artery, middle cerebral artery M1 segment) and high END risk may favor more aggressive intervention, while distal occlusions (e.g., M2 segment) often respond adequately to medical therapy with close monitoring. Clinical recommendations emphasize an individualized approach: prioritizing medical management for most patients, with EVT reserved for high-risk cases or those with neurological deterioration during observation. Future randomized controlled trials are needed to refine patient selection criteria and validate risk stratification tools for this challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.